NEFERTARI
Diagnosed with Heart Failure

Actual patient who consented to appear.

Cytokinetics®

Cytokinetics is a late-stage specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining.

By directly targeting the sarcomere, the foundation of muscle contraction, the treatments we are developing have the potential to preserve and extend independence and self-reliance in people suffering from diseases like heart failure, hypertrophic cardiomyopathy and other cardiovascular diseases. As a leader in muscle biology and the mechanics of muscle performance, Cytokinetics is developing small molecule drug candidates specifically engineered to myocardial impact muscle function and contractility.

Empowering Muscle. Empowering Lives.

QUICK FACTS

NASDAQ Symbol: CYTK

Operations began in 1998 Headquarters:
South San Francisco, CA

ANALYST COVERAGE

Bank of America, *Jason Zemansky, Ph.D.*
Barclays, *Carter Gould*
Cantor Fitzgerald, *Charles Duncan, Ph.D.*
H.C Wainwright, *Joseph Pantginis, Ph.D.*
Jefferies, *Akash Tewari*
JMP Securities, *Jason Butler, Ph.D.*
J.P. Morgan, *Tessa Romero*
Leerink Partners, *Roanna Ruiz, Ph.D*
Mizuho, *Salim Syed*
Morgan Stanley, *Jeff Hung*
Needham & Company, *Serge Belanger*
Oppenheimer & Co., *Justin Kim*
Piper Sandler, *Yasmeen Rahimi*
Raymond James, *Dane Leone*
Truist, *Srikripa Devarakonda, Ph.D.*
UBS, *Ashwani Verma*

Contact, Media & Investor:
Diane Weiser
650-624-3060
investor@cytokinetics.com
media@cytokinetics.com

robust pipeline

Cytokinetics was founded in 1997 by pioneers in the field of muscle biology. Since operations began in 1998, over the years, the company has developed an unparalleled expertise, keeping it at the forefront of drug discovery and development for diseases impacting muscle performance, with more than 115 publications, over 100 clinical trials, and hundreds of issued patents. Today Cytokinetics has 5 clinical stage programs and research ongoing in muscle function and contractility, energetics and metabolism.

PIPELINE OF NOVEL MUSCLE-DIRECTED DRUG CANDIDATES



*MAA on file with EMA
**Phase 3 study met criteria for futility; to date, no further study activity planned

All drug candidates are investigational products and have not been approved by any regulatory agencies; their safety and efficacy for anyindication has not been established.

At Cytokinetics we believe that serious diseases deserve serious attention.

the sarcomere: the key to muscle contraction

The principal functionality of muscle is rooted in its ability to contract and relax. The foundation for muscle contraction is the sarcomere. Sarcomeres contain a motor protein called myosin, which powers the muscle to contract by "grabbing" onto another protein called actin and "flexing." When the myosin releases the actin, the muscle relaxes. This process is regulated by another protein called troponin. At Cytokinetics, we have focused on these crucial proteins within muscle cells as the keys to unlock the treatment of diseases that are caused by impaired muscle function.



potential medicines

Aficamten • **CARDIAC MYOSIN INHIBITOR**

Aficamten is a selective small molecule next-in-class cardiac myosin inhibitor designed to reduce the hypercontractility associated with hypertrophic cardiomyopathy (HCM). HCM causes the heart to thicken and stiffen, eventually limiting its ability to pump blood. This happens when too many myosin heads bind with actin, resulting in a hypercontractile state. *Aficamten* reduces hypercontractility by inhibiting myosin from binding to actin.

CK-4021586 (CK-586) • **CARDIAC MYOSIN INHIBITOR**

CK-586 is a selective small molecule additional cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction (HFpEF). Like *aficamten*, CK-586 reduces hypercontractility by inhibiting myosin from binding to actin. However, CK-586 has a mechanism of action that's distinct from aficamten.

Omecamtiv mecarbil • **CARDIAC MYOSIN ACTIVATOR**

Omecamtiv mecarbil is a selective cardiac myosin activator being developed for the potential treatment of heart failure with reduced ejection fraction (HFrEF). *Omecamtiv mecarbil* stimulates cardiac myosin, and is designed to improve cardiac muscle performance, potentially helping patients avoid hospitalizations.

CK-3828136 (CK-136) • **CARDIAC TROPONIN ACTIVATOR**

CK-136 is a novel, selective, oral, small molecule cardiac troponin activator. In preclinical models, CK-136 increased myocardial contractility by binding to cardiac troponin through an allosteric mechanism that sensitizes the cardiac sarcomere to calcium, facilitating more actin-myosin cross bridge formation during each cardiac cycle thereby resulting in increased myocardial contractility.

our values

PATIENTS ARE OUR NORTH STAR
We seek to understand the patient's journey and proactively embed their needs in our goals. We keep the patient front and center in all we do.

SCIENCE IS IN OUR SOUL
We are committed to robust scientific thinking, grounded in integrity and critical thinking.

WE > ME
We are stronger as a team, valuing the power of diversity, rising together as one.

MAKE IT HAPPEN
We are all creating something truly special and hold ourselves accountable.

dedicated to diversity, equity, inclusion & respect

We are committed to creating a respectful and supportive workplace, and we pledge to advance a culture where everyone is valued, recognized, and encouraged to be their authentic selves. Innovation and ingenuity are powered by the varying ideas, cultures, and backgrounds that comprise our team. We champion diversity and inclusivity across all levels of our organization and consider these tenets to be vital to our collective success.

Cytokinetics, Inc.
350 Oyster Point Blvd., South San Francisco, CA 94080
650-624-3000 | **cytokinetics.com**